Agenus Has Completed Enrollment In ACTIVATE-Colorectal Phase 2 Trial For Advanced Colorectal Cancer Evaluating Botensilimab As Monotherapy And In Combination With Balstilimab Or Standard Of Care
Portfolio Pulse from Benzinga Newsdesk
Agenus has completed enrollment in its ACTIVATE-Colorectal Phase 2 trial for advanced colorectal cancer. The trial is evaluating Botensilimab as a standalone treatment and in combination with Balstilimab or standard care.
October 10, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agenus has completed enrollment for its Phase 2 trial, which could potentially lead to positive results and increased investor confidence.
The completion of enrollment for a Phase 2 trial is a significant milestone for any biotech company. This could potentially lead to positive results, which would increase investor confidence and potentially lead to a rise in the stock price. However, the actual impact will depend on the results of the trial.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100